Your browser doesn't support javascript.
loading
MYH9: A key protein involved in tumor progression and virus-related diseases.
Liu, Qing; Cheng, Chao; Huang, Jiyu; Yan, Weiwei; Wen, Yinhao; Liu, Zhen; Zhou, Beixian; Guo, Suiqun; Fang, Weiyi.
Afiliación
  • Liu Q; Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510315, China.
  • Cheng C; Department of Otolaryngology, Shenzhen Longgang Otolaryngology hospital, Shenzhen 518000, China.
  • Huang J; Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510315, China.
  • Yan W; Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510315, China.
  • Wen Y; Department of Oncology, Pingxiang People's Hospital, Pingxiang 337000, China.
  • Liu Z; Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510315, China; Key Laboratory of Protein Modification and Degradation, Basic School of Guangzhou Medical University, Guangzhou 510315, China. Electronic address: narcissus_jane@163.com.
  • Zhou B; The People's Hospital of Gaozhou, Gaozhou 525200, China. Electronic address: zbeixian@126.com.
  • Guo S; Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510315, China. Electronic address: guosq2005@126.com.
  • Fang W; Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510315, China; The People's Hospital of Gaozhou, Gaozhou 525200, China; Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510315,
Biomed Pharmacother ; 171: 116118, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38181716
ABSTRACT
The myosin heavy chain 9 (MYH9) gene encodes the heavy chain of non-muscle myosin IIA (NMIIA), which belongs to the myosin II subfamily of actin-based molecular motors. Previous studies have demonstrated that abnormal expression and mutations of MYH9 were correlated with MYH9-related diseases and tumors. Furthermore, earlier investigations identified MYH9 as a tumor suppressor. However, subsequent research revealed that MYH9 promoted tumorigenesis, progression and chemoradiotherapy resistance. Note-worthily, MYH9 has also been linked to viral infections, like severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Epstein-Barr virus, and hepatitis B virus, as a receptor or co-receptor. In addition, MYH9 promotes the development of hepatocellular carcinoma by interacting with the hepatitis B virus-encoding X protein. Finally, various findings highlighted the role of MYH9 in the development of these illnesses, especially in tumors. This review summarizes the involvement of the MYH9-regulated signaling network in tumors and virus-related diseases and presents possible drug interventions on MYH9, providing insights for the use of MYH9 as a therapeutic target for tumors and virus-mediated diseases.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones por Virus de Epstein-Barr / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Biomed Pharmacother Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones por Virus de Epstein-Barr / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Biomed Pharmacother Año: 2024 Tipo del documento: Article País de afiliación: China